On Sunday, at the 2023 ObesityWeek conference in Dallas, Lilly presented the full results from its SURMOUNT-3 trial, which found that after 72 weeks, people who took tirzepatide, the drug found in Mounjaro, lost about 60 pounds, while those who got a placebo regained weight
Tirzepatide (Mounjaro, Zepbound) is a related but distinct medication that acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist
Semaglutide, a medication for type 2 diabetes, is marketed under the name Wegovy
Semaglutide This is a GLP-1 agonist - and is the active ingredient or drug in Ozempic and Wegovy
Similar content being viewed by others Introduction The increasing global incidence of obesity is a major public health concern, escalating at a concerning rate and posing significant challenges to healthcare systems worldwide 1